Amphiregulin Mediates Estrogen, Progesterone, and EGFR Signaling in the Normal Rat Mammary Gland and in Hormone-Dependent Rat Mammary Cancers

Hormones and Cancer

Volumn 1, Issue 5, 2010, Pages 229-244

  Kariagina, Anastasia ^a   Xie, Jianwei ^a   Leipprandt, Jeffrey R ^a   Haslam, Sandra Z ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Amphiregulin; EGFR; Estradiol; Mammary cancer; Mammary gland; Progesterone; Progesterone receptor; Proliferation

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROMEGESTONE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL PROLIFERATION; DRUG MECHANISM; ENZYME ACTIVATION; IN VIVO STUDY; MAMMARY GLAND; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASMS, HORMONE-DEPENDENT; PROGESTERONE; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 78650208471     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-010-0048-0     Document Type: Article

References (59)

1. Bernstein L (2002) Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 7: 3-15.
2. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F (2005) Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 96: 95-108.
3. Graham JD, Clarke CL (2002) Expression and transcriptional activity of progesterone receptor A and progesterone receptor B in mammalian cells. Breast Cancer Res 4: 187-190.
4. Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius CA, Takimoto GS, Horwitz KB (2006) Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol 20: 2656-2670.
5. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP (2007) The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol 21: 359-375.
6. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM (2000) Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 289: 1751-1754.
7. Shyamala G, Yang X, Silberstein G, Barcellos-Hoff MH, Dale E (1998) Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc Natl Acad Sci USA 95: 696-701.
8. Aupperlee MD, Haslam SZ (2007) Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland. Endocrinology 148: 2290-2300.
9. Lange CA, Richer JK, Shen T, Horwitz KB (1998) Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 273: 31308-31316.
10. Daniel AR, Qiu M, Faivre EJ, Ostrander JH, Skildum A, Lange CA (2007) Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. Steroids 72: 188-201.
11. Faivre EJ, Lange CA (2007) Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 27: 466-480.
12. Pierson-Mullany LK, Lange CA (2004) Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol 24: 10542-10557.
13. Faivre EJ, Daniel AR, Hillard CJ, Lange CA (2008) Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol 22: 823-837.
14. Taylor D, Pearce CL, Hovanessian-Larsen L, Downey S, Spicer DV, Bartow S, Pike MC, Wu AH, Hawes D (2009) Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast. Breast Cancer Res Treat 118: 161-168.
15. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ (1990) Comparative study of human and rat mammary tumorigenesis. Lab Invest 62: 244-278.
16. Russo J, Russo IH (1996) Experimentally induced mammary tumors in rats. Breast Cancer Res Treat 39: 7-20.
17. Silberstein GB, van Horn K, Shyamala G, Daniel CW (1994) Essential role of endogenous estrogen in directly stimulating mammary growth demonstrated by implants containing pure antiestrogens. Endocrinology 134: 84-90.
18. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, Horwitz KB (1994) New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 54: 3868-3877.
19. Haslam SZ, Drolet A, Smith K, Tan M, Aupperlee M (2008) Progestin-regulated luminal cell and myoepithelial cell-specific responses in mammary organoid culture. Endocrinology 149: 2098-20107.
20. Mote PA, Johnston JF, Manninen T, Tuohimaa P, Clarke CL (2001) Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol 54: 624-630.
21. Kariagina A, Aupperlee MD, Haslam SZ (2007) Progesterone receptor isoforms and proliferation in the rat mammary gland during development. Endocrinology 148: 2723-2736.
22. Chen H, Kovar J, Sissons S, Cox K, Matter W, Chadwell F, Luan P, Vlahos CJ, Schutz-Geschwender A, Olive DM (2005) A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Anal Biochem 338: 136-142.
23. Kariagina A, Romanenko D, Ren SG, Chesnokova V (2004) Hypothalamic-pituitary cytokine network. Endocrinology 145: 104-112.
24. Kariagina A, Zonis S, Afkhami M, Romanenko D, Chesnokova V (2005) Leukemia inhibitory factor regulates glucocorticoid receptor expression in the hypothalamic-pituitary-adrenal axis. Am J Physiol Endocrinol Metab 289: E857-863.
25. Ciarloni L, Mallepell S, Brisken C (2007) Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci USA 104: 5455-5460.
26. Sternlicht MD, Sunnarborg SW (2008) The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J Mammary Gland Biol Neoplasia 13: 181-194.
27. Kim NS, Kim HJ, Koo BK, Kwon MC, Kim YW, Cho Y, Yokota Y, Penninger JM, Kong YY (2006) Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol 26: 1002-1013.
28. Turashvili G, Bouchal J, Burkadze G, Kolar Z (2006) Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 73: 213-223.
29. Brisken C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, McMahon JA, McMahon AP, Weinberg RA (2000) Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 14: 650-654.
30. Cao Y, Karin M (2003) NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 8: 215-223.
31. Rowlands TM, Pechenkina IV, Hatsell S, Cowin P (2004) Beta-catenin and cyclin D1: connecting development to breast cancer. Cell Cycle 3: 145-148.
32. Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD (2008) Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 283: 739-750.
33. Cui X, Kim HJ, Kuiatse I, Kim H, Brown PH, Lee AV (2006) Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res 66: 5304-5313.
34. Lange CA, Shen T, Horwitz KB (2000) Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 97: 1032-1037.
35. Pei RJ, Sato M, Yuri T, Danbara N, Nikaido Y, Tsubura A (2003) Effect of prenatal and prepubertal genistein exposure on N-methyl-N-nitrosourea-induced mammary tumorigenesis in female Sprague-Dawley rats. In Vivo 17: 349-357.
36. Mote PA, Bartow S, Tran N, Clarke CL (2002) Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 72: 163-172.
37. Aupperlee MD, Smith KT, Kariagina A, Haslam SZ (2005) Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology 146: 3577-3588.
38. Gallo D, Zannoni GF, Martinelli E, Ferlini C, Fabrizi M, Riva A, Morazzoni P, Bombardelli E, Scambia G (2006) Estradiol and phytoestrogens differently influence the rodent postmenopausal mammary gland. Menopause 13: 72-79.
39. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84: 4559-4565.
40. Clarke RB (2003) Steroid receptors and proliferation in the human breast. Steroids 68: 789-794.
41. Russo J, Ao X, Grill C, Russo IH (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53: 217-227.
42. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI (2006) Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96: 131-146.
43. Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB (2006) Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer 13: 617-628.
44. Matsumoto K, Fukuda S, Nakamura Y, Saito H (2009) Amphiregulin production by human eosinophils. Int Arch Allergy Immunol 149(Suppl 1): 39-44.
45. Brunelli E, Pinton G, Chianale F, Graziani A, Appendino G, Moro L (2009) 8-Prenylnaringenin inhibits epidermal growth factor-induced MCF-7 breast cancer cell proliferation by targeting phosphatidylinositol-3-OH kinase activity. J Steroid Biochem Mol Biol 113: 163-170.
46. Cicenas J (2008) The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 23: 1-9.
47. Shaulian E, Karin M (2001) AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400.
48. Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PH (2006) The AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol 295: 589-603.
49. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277: 5209-5218.
50. Lange CA, Richer JK, Horwitz KB (1999) Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 13: 829-836.
51. Bamberger AM, Milde-Langosch K, Schulte HM, Loning T (2000) Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res 54: 32-37.
52. McGowan EM, Clarke CL (1999) Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. Mol Endocrinol 13: 1657-1671.
53. Shen T, Horwitz KB, Lange CA (2001) Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol 21: 6122-6131.
54. Lubet RA, Szabo E, Christov K, Bode AM, Ericson ME, Steele VE, Juliana MM, Grubbs CJ (2008) Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes. Mol Cancer Ther 7: 972-979.
55. Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, Gridelli C, Catalano G, De Placido S, Bianco AR (2006) Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 94: 1604-1609.
56. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304: 1684-1692.
57. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98-102.
58. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468: 103-107.
59. Aupperlee MD, Drolet AA, Durairaj S, Wang W, Schwartz RC, Haslam SZ (2009) Strain-specific differences in the mechanisms of progesterone regulation of murine mammary gland development. Endocrinology 150: 1485-1494.